NCE-1 Intelligence & Market Opportunity

Lytgobi

Futibatinib

Anticancer

Oral Tablet

Approval Date

30-Sep-22

NCE-1 Date

30-Sep-26

NCE Date

30-Sep-27

Commercial snapshot

Market performance & projections

Revenue ($M)

CAGR (%)

0.0367

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

2027

2028

2029

2030

2031

2032

Molecule profile

Details & specifications

Molecule

Futibatinib

Innovator

TAIHO PHARMACEUTICAL CO., LTD.

Dosage Form

Oral Tablet

Strength

16 mg, 4 mg

Therapeutic Category

Anticancer

Usage

To treat intrahepatic cholangiocarcinoma harboring fibroblast growth factor receptor 2 (FGFR2) gene fusions or other rearrangements

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.